Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (June 2019)
27 slides from Artelo Biosciences's investor presentation, June 2019
Slide 1: Clinical stage biopharmaceutical company targeting the endocannabinoid system
A clinical stage biopharmaceutical company developing and commercializing a portfolio of novel therapeutic candidates targeting the endocannabinoid system OTCQB: ARTL June 2019
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation of Artelo Biosciences, Inc. (the “Company”) that are not historical facts are "forward-looking statements" subject to risks/uncertainties. Such statements are based on current facts/analyses and other information that are based on forecasts
Slide 3: Company Highlights
Company Highlights NOVEL DRUG ROBUST NEAR-TERM BILLION DOLLAR PROVEN PIPELINE PATENT ESTATE MILESTONES MARKETS LEADERSHIP 3
Slide 4: Vast Therapeutic Potential of Endocannabinoid System (ECS) Modulation
Vast Therapeutic Potential of Endocannabinoid System (ECS) Modulation The ECS is a family of receptors and neurotransmitters that form a biochemical communication network throughout the body “Modulating ECS activity holds therapeutic promise for a broad range of diseases, including neurodegenerative
Slide 5: Pipeline
Pipeline Product Candidate Pre-clinical Phase 1 Phase 2 Market Size* ART 27.13 Cancer Anorexia Cachexia Anorexia associated with Cancer Cannabinoid Agonist Syndrome: $2B Inflammatory Bowel IBD (Crohn’s & Colitis): $7B Disease ART 12.11 CBD Cocrystal Post-Traumatic Stress Disorder: PTSD $7B Prostate
Slide 6: Patent Estate & Licenses
Patent Estate & Licenses Product Candidate Patent Status License ART 27.13 Two (2) issued patents (US & Intl) including Worldwide exclusive license* Cannabinoid Agonist composition of matter, term 11/3/25 ART 12.11 Pending composition of matter applications N/A (owned by Artelo) CBD Cocrystal (US &
Slide 7: ART 27.13 Cancer Anorexia Clinical Program
ART 27.13 CANCER ANOREXIA CLINICAL PROGRAM
Slide 8: Cancer Anorexia and Cachexia Syndrome Remains a High Unmet Need
Cancer Anorexia and Cachexia Syndrome (CACS) Remains a High Unmet Need ART 27.13 CANCER ANOREXIA CLINICAL PROGRAM Currently there are no approved drugs for CACS • Cancer-related anorexia affects about 60% of advanced stage cancer patients • Despite absence of convincing data, appetite stimulants are
Slide 9: Advantage of Cannabinoid Agonist that Targets Body not the Brain
Advantage of Cannabinoid Agonist that Targets Body not the Brain ART 27.13 CANCER ANOREXIA CLINICAL PROGRAM Peripheral acting ART27.13 avoids undesired side effects of other high potency cannabinoids Monkey PET Scan with [11C]- Sends feeding ART27.13 Brain: Plasma Ratio = 0.5 signal to the brain Tar
Slide 10: Link Between Cannabinoids and Appetite is Well Established
Link Between Cannabinoids and Appetite is Well Established ART 27.13 CANCER ANOREXIA CLINICAL PROGRAM Exposure and weight gain correlation observed in a phase 1 study of ART27.13 Over 12 days, 25% of subjects gained 3% or greater of baseline body weight Acceptable side effect profile at the intended
Slide 11: Unique Among Late Stage Agents Targeting CACS
Unique Among Late Stage Agents Targeting CACS ART 27.13 CANCER ANOREXIA CLINICAL PROGRAM Set of attributes are differentiated from other current Phase 2 and Phase 3 programs • Peripherally restricted synthetic new chemical entity • Differentiated mechanism of action • High-potency dual CB1/CB2 canna
Slide 12: Planned Phase 1b/2a Study in Anorexia Associated with Cancer
Planned Phase 1b/2a Study in Anorexia Associated with Cancer ART 27.13 CANCER ANOREXIA CLINICAL PROGRAM Study: A Phase 1b/2a, Randomized, Placebo-Controlled Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss Objectives: • Phase 1b - Determine the most effect
Slide 13: ART 12.11 Proprietary CBD Cocrystal Program
ART 12.11 PROPRIETARY CBD COCRYSTAL PROGRAM
Slide 14: Creating a Better Cannabidiol (CBD)
Creating a Better Cannabidiol (CBD) ARTART We are developing a more attractive CBD for pharmaceutical development 12.11 12.11PROPRIETARY What is good about CBD? What could be better? Our solution PROPRIETARY COCRYSTAL CBD is a chemical that has known CBD is in the public domain with CBD cocrystal me
Slide 15: Cocrystals are Accepted in Pharmaceuticals and New to CBD
Cocrystals are Accepted in Pharmaceuticals and New to CBD ARTART CBD cocrystal leverages an innovative, USPTO and FDA supported pharmaceutical strategy 12.11 12.11PROPRIETARY CBD PROPRIETARY COCRYSTAL CBD Cocrystalization CBD Drug Coformer CBD Cocrystal CBD COCRYSTAL Therapeutic Innovator FDA Indica
Slide 16: Competitive Advantages of Next-Generation CBD Cocrystal
Competitive Advantages of Next-Generation CBD Cocrystal ARTART Potential next-generation benefits are derived from multiple proprietary features 12.11 12.11PROPRIETARY Proprietary Features Expected Benefits Unique new chemical entity Proprietary to Artelo with worldwide market exclusivity PROPRIET
Slide 17: Priority Indications for Development of Proprietary CBD Cocrystal
Priority Indications for Development of Proprietary CBD Cocrystal ARTART Anti-anxiety and anti-inflammation activity of CBD supports development in PTSD and IBD 12.11 12.11PROPRIETARY Post-Traumatic Stress Disorder Inflammatory Bowel Diseases • Anxiety disorder caused by very stressful, frightening
Slide 18: ART 26.12 FABP5 Inhibitor
ART 26.12 3 Artelo FABP5 INHIBITOR 7 BIOSCIENCES
Slide 19: Lipid Signaling Pathways are a Next-Generational Target for Cancer Therapeutics
Lipid Signaling Pathways are a Next-Generational Target for Cancer Therapeutics FABP5 inhibitor was developed at Stony Brook University with multi-million dollar NIH funding ART 26.12 FABP5 INHIBITOR • FABP5 is an intra-cellular protein that serves as a carrier for certain lipids, including endocann
Slide 20: FABP5 is a Validated Target in Breast, Prostate, and Cervical Cancer
FABP5 is a Validated Target in Breast, Prostate, and Cervical Cancer ART 26.12 FABP5 INHIBITOR Genetic silencing of FABP5 is anti-tumor (A) FABP5 correlates with tumor grade (B), is upregulated in triple negative breast cancer (C), and is associated with poor prognosis (D). ART 26.12 FAB5 INHIBITOR
Slide 21: FABP5 Inhibitor Decreases Tumor Growth in Prostate Cancer Model
FABP5 Inhibitor Decreases Tumor Growth in Prostate Cancer Model ART 26.12 FABP5 INHIBITOR SBFI26 = ART26.12 ART 26.12 FAB5 INHIBITOR Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5 W. Al-Jameel, Oncotarget, 2017, V
Slide 22: Company
COMPANY i Ze Artelo
Slide 23: Planned Activities and Milestones
Planned Activities and Milestones 2019 2020 ART 27.13 MANUFACTURE PHASE 2 CANCER ANOREXIA STUDY Cannabinoid Agonist CLINICAL SUPPLY PROCESS CHEMISTRY Expecting REGULATORY MANUFACTURING to begin ART 12.11 SCALE UP ADVICE MEETING 2021 with CBD Cocrystal three REGULATORY programs INVESTIGATIONAL APPLIC
Slide 24: Proven Leadership
Proven Leadership MANAGEMENT TEAM BOARD OF DIRECTORS SCIENTIFIC COLLABORATORS GREGORY GORGAS* CONNIE MATSUI SAOIRSE O’SULLIVAN, PhD President & CEO, Director Chair of the Board Cannabinoid Professor, University BiogenIdec, Chiron, Cetus, Upjohn Nominating & Governance Committee Chair of Nottingham,
Slide 25: Company Capitalization
Company Capitalization As of May 28, 2019 Series A warrant strike price - $1.00 (# 390,461) Series B warrant strike price - $1.50 (# 261,779) Market Cap USD $20.3M Series C warrant strike price - $1.75 (# 140,220) Series D warrant strike price - $1.75 (# 256,079) Series E Warrant strike price - $2.0
Slide 26: Summary
Summary NOVEL DRUG ROBUST NEAR-TERM BILLION DOLLAR PROVEN PIPELINE PATENT ESTATE MILESTONES MARKETS LEADERSHIP Developing federally Comprehensive issued (4) Clinical milestone Target indications for the Experienced team of regulated therapeutics and pending (4) patents readout expected for portfolio
Slide 27: For more information: www.artelobio.com
For more information: www.artelobio.com
Artelo Biosciences — Investor Presentation (June 2019) on 6ix